The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Have platinum-resistant disease.
Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum containing regimen.
Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.
Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer.
Have primary platinum-refractory disease, defined as progression on or within 3 months after the last dose of first line platinum-containing therapy.
Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study treatment.
Known active CNS metastases and/or carcinomatous meningitis.
Incyte Corporation
Lead sponsor
ENGOT Foundation
Collaborator
GOG Foundation
Collaborator